AlphaTON Executes Binding Call Option Agreement with Immunova for iOx Acquisition

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 17 2026

0mins

ATON-5.09%

Should l Buy ATON?

Source: Newsfilter

Acquisition Agreement Signed: AlphaTON Capital has executed a binding call option agreement with Immunova, allowing Immunova to acquire its wholly-owned subsidiary iOx Therapeutics, which is expected to yield over $100 million in milestone payments and single-digit royalties on future sales for AlphaTON.
Clinical Candidate Progress: iOx's lead candidate, PORT-2, has shown promising results in clinical trials for advanced melanoma and metastatic NSCLC in the U.S. and U.K., demonstrating anti-tumor activity and enhancing AlphaTON's competitive edge in the biotechnology sector.
Strategic Investment Opportunity: This transaction enables AlphaTON to unlock value from iOx while maintaining significant participation in its future success through equity stakes and milestone payments, further solidifying its position in the biotech industry.
Future Development Plans: AlphaTON will continue to advance its mesothelioma program and plans to launch a new AI-driven biotech initiative within the Telegram ecosystem, aiming to maximize overall portfolio value through diversified investment strategies.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ATON?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ATON

About ATON

AlphaTON Capital Corp., formerly Portage Biotech Inc., is a specialized digital asset treasury company. The Company is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The Company implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. It is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The Company engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

AlphaTON Capital Corp. Provides Market Update on Shares and Warrants

Feb 19 2026Newsfilter

Share Overview: As of February 19, 2026, AlphaTON Capital Corp. has 23,434,588 ordinary shares outstanding, indicating the company's stability and investor confidence in its market position.
Warrant Details: The company has 1,373,686 ordinary shares issuable upon the exercise of outstanding warrants at a weighted average exercise price of $11.62 per share, reflecting expectations for future stock price appreciation.
Equity Incentive Plan: Under the 2021 Equity Incentive Plan, 316,111 ordinary shares are issuable upon the exercise of share options with a weighted average exercise price of $40.65 per share, highlighting the company's commitment to executive incentives.
Restricted Share Units: The company has 5,410 ordinary shares issuable upon the vesting of restricted share units, further enhancing the long-term incentive mechanism for employees.

AlphaTON Capital Unveils AI Strategy and Future Plans

Feb 18 2026Newsfilter

AI Infrastructure Revolution: Brittany Kaiser, CEO of AlphaTON Capital, announced that the deployment of H200 and B200 alongside the #OwnYourNode initiative signifies a fundamental shift in AI infrastructure ownership and operation, enabling everyday individuals to participate in the decentralized AI revolution, which is expected to significantly enhance user engagement and market competitiveness.
Privacy-First AI Network: Cocoon AI has become the world's first large-scale privacy-first AI network on Telegram, experiencing a 340% month-over-month growth in user base, which not only elevates AlphaTON's market position in the AI sector but also lays a solid foundation for future revenue growth.
Superapp Economy: AlphaTON is building the compute backbone of the Telegram economy, leveraging its market potential with 1 billion users, and is expected to drive the company's leadership in the rapidly evolving superapp market by providing privacy-preserving and confidential computing services.
Strategic Investment and Market Expansion: Through strategic investments in the Telegram ecosystem, AlphaTON Capital offers institutional-grade market exposure, which is anticipated to attract more investor interest in its potential within decentralized finance and application development, thereby driving long-term growth for the company.